REG - IXICO plc - Notice of half year results

IXICOAnnouncement

07/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG2578Na&default-theme=true

RNS Number : 2578N  IXICO plc  07 May 2024

7 May 2024

IXICO plc

("IXICO" or the "Company")

 

Notice of half-year results and investor presentation via Investor Meet
Company.

IXICO PLC is pleased to announce that it will release its half-year results on
Tuesday 21 May 2024.

Giulio Cerroni and Grant Nash will provide a live presentation relating to
these results and a broader Company update via Investor Meet Company on 21 May
2024, 16:30 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
20 May 2024, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C02%7Cgrant.nash%40ixico.com%7Cf18beb8f3a0447cab24008dc629e5240%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638493679356429058%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=P0xfOt1l612Fi5i9gswZaWfyjFCzsLe1XBKDVrCU710%3D&reserved=0)

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

For further information please contact:

 

 IXICO plc                                                                               +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated adviser and sole broker)                   +44 (0) 20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks/Harriet Ward (Corporate Broking)
 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBLGDUSBGDGSX